Physician profile
Constance W Strbich
NPI 1033148978
$2,033.50
in general payments reported to CMS, 2019-2025
26 companies · $198 in 2025
The $198 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $816 · 2020: $123 · 2022: $53.55 · 2023: $461 · 2024: $382 · 2025: $198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $981 · Education: $60.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $980.69 |
| Education | $60.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $344.47 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $223.84 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $187.78 | 2020-2024 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $176.50 | 2019 | |
| Lilly USA, LLC | $166.76 | 2022-2025 | Mounjaro, Zepbound |
| Astellas Pharma US INC | $165.39 | 2019-2025 | Veozah |
| Novo Nordisk INC | $136.51 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $133.55 | 2024-2025 | Airsupra, Breztri |
| Amgen INC. | $67.08 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $55.06 | 2019-2020 | |
| Mylan Specialty L.P. | $38.71 | 2019 | |
| Boston Scientific Corporation | $37.19 | 2023 | Watchman Flx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.64 | 2019 | |
| Sanofi-Aventis U.S. LLC | $30.25 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $29.96 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $29.73 | 2024 | |
| Ironshore Pharmaceuticals INC. | $24.94 | 2019-2020 | |
| Amarin Pharma, INC. | $22.64 | 2022 | |
| Paratek Pharmaceuticals, INC. | $22.19 | 2025 | Xhance, Nuzyra |
| Dexcom, INC. | $19.32 | 2023 | Dexcom G6 Transmitter |
| Currax Pharmaceuticals LLC | $16.10 | 2025 | Contrave |
| Abbvie INC. | $16.02 | 2019 | |
| Ucb, INC. | $13.87 | 2019 | |
| Radius Health, INC. | $13.74 | 2019 | |
| Neurocrine Biosciences, INC. | $13.25 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Constance Strbich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.